Various senolytics, including ABT-263, interfere with the antiapoptotic proteins Bcl-2, Bcl-w, and Bcl-XL (160) and have been investigated for their ability to eliminate senescent tumor cells that are induced by etoposide, doxorubicin, cisplatin, and radiation. This evidence concerns the gene BCL2 and neoplasm.